We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
-10.7%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$11.7B
AUM Growth
-$3.17B
Cap. Flow
-$1.15B
Cap. Flow %
-9.88%
Top 10 Hldgs %
46.25%
Holding
136
New
17
Increased
36
Reduced
23
Closed
34

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$440M
2
IQV icon
IQVIA
IQV
+$269M
3
AGN
Allergan plc
AGN
+$247M
4
GD icon
General Dynamics
GD
+$183M
5
FIS icon
Fidelity National Information Services
FIS
+$158M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$793M
2
MDCO
Medicines Co
MDCO
+$282M
3
ZAYO
Zayo Group Holdings, Inc.
ZAYO
+$236M
4
SPGI icon
S&P Global
SPGI
+$175M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$104M

Sector Composition

Rank Sector Weight
1 Healthcare 52.14%
2 Communication Services 12.39%
3 Technology 10.92%
4 Industrials 5.44%
5 Financials 3.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCYT icon
51
Veracyte
VCYT
$3.4B
$33.4M 0.29%
1,375,000
+375,000
+38% +$9.44M
PGNX
52
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$31.4M 0.27%
8,250,000
– –
TVRD
53
Tvardi Therapeutics
TVRD
$24.8M
$30.4M 0.26%
63,889
– –
ARWR icon
54
Arrowhead Research
ARWR
$12.3B
$28.8M 0.25%
1,000,000
+900,000
+900% +$36.3M
FSCT
55
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
$27.6M 0.24%
+875,000
New +$27.4M
TECX
56
Tectonic Therapeutic
TECX
$736M
$26.8M 0.23%
143,750
+14,583
+11% +$3.43M
RDUS
57
DELISTED
Radius Health, Inc.
RDUS
$26.7M 0.23%
2,054,486
– –
ZEAL
58
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$25.9M 0.22%
750,000
-259,800
-26% -$9.05M
KPTI icon
59
Karyopharm Therapeutics
KPTI
$44.5M
$25.6M 0.22%
+89,000
New +$24.5M
NVTA
60
DELISTED
Invitae Corporation
NVTA
$25.6M 0.22%
1,875,300
+125,300
+7% +$2.29M
MNTA
61
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$22.9M 0.2%
842,683
-1,907,317
-69% -$53.1M
PRNB
62
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$22.8M 0.2%
384,674
-15,326
-4% -$893K
TCDA
63
DELISTED
Tricida, Inc. Common Stock
TCDA
$22M 0.19%
1,000,000
– –
MYOK
64
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$20.2M 0.17%
430,000
-1,620,000
-79% -$104M
SAGE
65
DELISTED
Sage Therapeutics
SAGE
$19.4M 0.17%
675,000
+175,000
+35% +$10.1M
BX icon
66
Blackstone
BX
$108B
$18.4M 0.16%
+402,811
New +$22.3M
BRMK
67
CALL
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$18M 0.15%
+2,391,536
New +$26.4M
CRSP icon
68
CRISPR Therapeutics
CRSP
$5.75B
$14.8M 0.13%
350,000
– –
AMRN
69
Amarin Corp
AMRN
$298M
$14.5M 0.12%
181,250
-25,000
-12% -$8.31M
ATRA icon
70
Atara Biotherapeutics
ATRA
$97.4M
$12.8M 0.11%
60,000
+46,612
+348% +$14.8M
QURE icon
71
uniQure
QURE
$3.36B
$11.9M 0.1%
250,000
+50,000
+25% +$2.87M
STML
72
DELISTED
Stemline Therapeutics, Inc.
STML
$11.4M 0.1%
2,350,000
– –
KRYS icon
73
Krystal Biotech
KRYS
$10.3B
$10.8M 0.09%
+250,000
New +$13.1M
PTGX icon
74
Protagonist Therapeutics
PTGX
$9.99B
$10.6M 0.09%
1,500,000
– –
SVRA icon
75
Savara
SVRA
$1.15B
$10.2M 0.09%
4,825,086
– –
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q1 2020 Portfolio in Review

As of Q1 2020, Thomas Steyer held 136 positions worth $11.7B, down 21% from $14.8B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Thomas Steyer withdrew a net $1.15B in Q1 2020, closing 34 positions and reducing 23 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $793M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 47% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in Centene worth $431M.

  • Thomas Steyer's largest Q1 2020 buy was Centene: 7,250,000 shares worth $431M.
  • Thomas Steyer added most to IQVIA in Q1 2020, an estimated $269M increase.
  • Thomas Steyer's biggest Q1 2020 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $104M.
  • Thomas Steyer fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $793M.
  • Thomas Steyer's ten largest holdings make up 46% of its $11.7B portfolio in Q1 2020.
  • Thomas Steyer opened 17 new positions and closed 34 in Q1 2020.
  • Thomas Steyer's portfolio value fell 21% quarter-over-quarter to $11.7B.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.